The Board of Directors of Affymax, Inc. (OTCPK:AFFY) is reviewing its strategic options as a result of the termination of the collaboration with Takeda Pharmaceutical Company Limited (TSE:4502). Affymax and Takeda would terminate their Omontys product partnership in September. The firms would also withdraw their new drug application with the U.S. Food and Drug Administration.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0007 USD | 0.00% |
|
0.00% | +16.67% |
1st Jan change | Capi. | |
---|---|---|
+16.67% | 52.14K | |
+22.15% | 46.56B | |
+45.60% | 41.67B | |
-2.37% | 41.16B | |
+33.84% | 32.4B | |
-6.35% | 28.1B | |
+20.42% | 28.18B | |
+48.83% | 14.52B | |
+45.00% | 13.74B | |
+0.06% | 12.17B |
- Stock Market
- Equities
- AFFY Stock
- News Affymax, Inc.
- Affymax To Review Strategic Options